Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Health Catalyst Inc’s stock clocked out at $3.98, up 0.51% from its previous closing price of $3.96. In other words, the price has increased by $0.51 from its previous closing price. On the day, 0.66 million shares were traded.
Ratios:
To gain a deeper understanding of HCAT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.24. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 0.44.
On January 08, 2025, KeyBanc Capital Markets Upgraded its rating to Overweight which previously was Sector Weight but kept the price unchanged to $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 05 ’25 when Landry Benjamin sold 6,057 shares for $3.94 per share. The transaction valued at 23,891 led to the insider holds 151,125 shares of the business.
BENJAMIN LANDRY bought 6,057 shares of HCAT for $23,925 on Jun 05 ’25. On Jun 02 ’25, another insider, Benjamin Landry, who serves as the Officer of the company, bought 3,255 shares for $3.63 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.89 while its Price-to-Book (P/B) ratio in mrq is 0.73.
Stock Price History:
Over the past 52 weeks, HCAT has reached a high of $9.24, while it has fallen to a 52-week low of $3.49. The 50-Day Moving Average of the stock is 0.39%, while the 200-Day Moving Average is calculated to be -35.12%.
Shares Statistics:
A total of 69.48M shares are outstanding, with a floating share count of 66.24M. Insiders hold about 4.83% of the company’s shares, while institutions hold 80.04% stake in the company.
Earnings Estimates
The current market rating for Health Catalyst Inc (HCAT) reflects the collective analysis of 10.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.08, with high estimates of $0.13 and low estimates of $0.05.
Analysts are recommending an EPS of between $0.39 and $0.16 for the fiscal current year, implying an average EPS of $0.24. EPS for the following year is $0.39, with 12.0 analysts recommending between $0.59 and $0.29.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $80.59M. It ranges from a high estimate of $81M to a low estimate of $80.37M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $75.9MFor the next quarter, 11 analysts are estimating revenue of $85.19M. There is a high estimate of $86.02M for the next quarter, whereas the lowest estimate is $84.3M.
A total of 13 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $335.12M, while the lowest revenue estimate was $330.1M, resulting in an average revenue estimate of $334.13M. In the same quarter a year ago, actual revenue was $306.58MBased on 13 analysts’ estimates, the company’s revenue will be $366.02M in the next fiscal year. The high estimate is $370.13M and the low estimate is $352.59M.
